Product Information:

SEM-O 7mg Tablets contain Semaglutide 7mg, an oral formulation of a GLP-1 receptor agonist used for the treatment of type 2 diabetes mellitus in adults. It is the intermediate maintenance dose in the oral semaglutide regimen, following successful initiation on the 3mg dose.

Oral semaglutide is formulated with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), an absorption enhancer that allows the peptide to be absorbed in the stomach.

✅ Note: This product aligns with the globally approved Rybelsus®-like oral semaglutide, where 7mg is a standard step-up dose after the initial 3mg phase.

Uses of (SEM-O 7MG TABS):

1. Type 2 diabetes mellitus – as part of ongoing glycemic management
2. Adjunct to diet and exercise to improve blood glucose control
3. May reduce cardiovascular risk in high-risk patients (based on injectable semaglutide data)

❌ Not approved for weight loss (unlike injectable Wegovy®). Oral semaglutide is indicated only for diabetes.

Key Benefits of (SEM-O 7MG TABS):

1. First and only oral GLP-1 receptor agonist available
2. Significant HbA1c reduction (up to 1.5–1.8%)
3. Promotes modest weight loss (~4–6 kg on average)
4. Once-daily dosing without injections
5. Low risk of hypoglycemia when not combined with insulin or sulfonylureas

How To Use (SEM-O 7MG TABS):

1. Take once daily in the morning, on a completely empty stomach.
2. Swallow whole with no more than 120 mL (4 oz) of plain water only.
3. Wait at least 30 minutes before eating, drinking (other than water), or taking other medications.
4. Do not split, crush, or chew the tablet.

Dosing Protocol:

1. Must start on 3mg once daily for ≥30 days
2. After ≥30 days, if additional glycemic control is needed, increase to 7mg once daily
3. May further escalate to 14mg once daily after another ≥30 days if required

When Not to Use (SEM-O 7MG TABS):

Do not use if you have:

1. Type 1 diabetes or diabetic ketoacidosis
2. Personal or family history of medullary thyroid carcinoma (MTC)
3. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
4. Hypersensitivity to semaglutide or any excipients

⚠️ Black Box Warning:

Semaglutide causes thyroid C-cell tumors in rodents. It is contraindicated in patients with a personal or family history of MTC or MEN 2.

Side Effects of (SEM-O 7MG TABS):

Common (usually mild to moderate, especially during dose escalation):

1. Nausea, vomiting, diarrhea, constipation
2. Abdominal pain, decreased appetite
3. Dyspepsia, bloating

Less common:

1. Fatigue, dizziness
2. Elevated amylase/lipase levels

Serious (rare but require monitoring):

1. Acute pancreatitis (persistent severe upper abdominal pain radiating to back)—discontinue immediately
2. Diabetic retinopathy complications (in patients with pre-existing retinopathy)
3. Acute kidney injury (due to dehydration from GI losses)
4. Gallbladder disorders (cholelithiasis, cholecystitis)
5. Seek emergency care if severe abdominal pain, vision changes, or persistent vomiting occurs.

Dosage: (SEM-O 7MG TABS):

1. Maintenance dose: 7mg once daily
2. Only initiate after completing ≥30 days on 3mg
3. Maximum dose: 14mg once daily

Who It’s For (SEM-O 7MG TABS):

Adults with type 2 diabetes who have completed the initiation phase on 3mg and require intensified glycemic control, and who can adhere to strict dosing instructions.

Warnings & Precautions:

1. Ensure adequate fluid intake to prevent dehydration
2. Monitor renal function periodically
3. Use caution in patients with diabetic retinopathy or gallbladder disease
4. Educate patients on proper administration to ensure absorption

Drug Interactions:

1. Other oral medications: Absorption may be delayed—administer ≥30 minutes apart
2. Insulin or sulfonylureas: Increased risk of hypoglycemia
3. Always inform your doctor about all medications and supplements.

Additional Information:

1. Store in original blister pack at room temperature (<30°C)
2. Keep out of reach of children
3. Available by prescription in Pakistan